U.S. Markets closed

Osiris Therapeutics, Inc. (OSIR)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
5.95+0.03 (+0.51%)
At close: 3:59PM EDT
People also watch
CYTXCURPSTIOPXAVNDA
  • the spread is $.01, why don't they meet in the middle and cancel each other out so we can get some real activity going on the stock this week. I'm looking for steady gains all week up to high $6's.
  • I've had a buy order with no restrictions in for a couple hrs at $5.70 Osir was at $6.00. Price went right mine down to $5.60 without taking any of my shares. Now the bid is at $5.75 and ask at $6.00. These crooks got it made and no I have never seen that happen before
  • This latest action closes the book on the "old" Osiris and it signals that ALL of the financials are complete and the E & Y audit is underway. It also tells us that nothing nefarious was uncovered, otherwise E & Y would not have signed on to be the official auditor of record. This is all good news and the era of the "new" Osiris has begun.
  • MDXG getting hammered early.
  • On May 15 Mr Law was informed that he will be replaced by Ms Chang.
    On May 16 E&Y declared its clients acceptance procedure as completed.
  • Form 8-K, looks like we've got a new CFO. Laws' last day 5/31/17

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    Appointment of Chief Financial Officer

    On May 19, 2017, Osiris Therapeutics, Inc. (the “Company”) announced the appointment of Linda Chang, age 51, as Chief Financial Officer, effective May 17, 2017. Ms. Chang was most recently Senior Vice President, Chief Financial Officer of Therabron Therapeutics from December 2015 to February 2017 where she led the Finance, Strategic Planning and Legal functions. Previously, Ms. Chang served as Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary at PharmAthene Inc., a NYSE-MKT listed company from November 2011 until April 2015. While there, Ms. Chang was responsible for all financial operations including corporate accounting, SEC reporting, tax, treasury, financial planning, investor relations and capital access. Prior to PharmAthene, Ms. Chang held roles of increasing responsibility in the financial groups at Human Genome Sciences, Booz Allen & Hamilton, Grant Thornton LLC and Otsuka America Pharmaceuticals.

    Ms. Chang has over 20 years of finance and executive leadership experience. She holds a B.S. in Business Administration from the University of California, Riverside, an M.B.A. as well as a Master of Accountancy degree from the University of Georgia. She is also Certified Public Accountant (inactive).

    Ms. Chang will receive an annual base salary of $320,000 and will be entitled to earn an annual performance-based bonus opportunity of up to 25% of her base salary. In addition, Ms. Chang will be entitled to participate in a long-term incentive plan to be designed by the Compensation Committee by or before December 31, 2017. In the event of a change in control of the Company any grants or awards under the long-term incentive plan shall immediately become vested. Ms. Change will be entitled to receive a severance payment equal to six months of her annual base salary if she is terminated without cause. She will also be entitled to participate in other benefit plans generally available to other employees of the Company.

    Departure of Chief Financial Officer

    On May 15, 2017, the Company notified Gregory I. Law, the Company’s former Chief Financial Officer, that the Company had hired Ms. Chang as his successor. Mr. Law’s separation date is May 31, 2017. The Company has agreed to pay Mr. Law his base salary, payable in accordance with the Company’s normal payroll schedule, until August 22, 2017. Mr. Law has also agreed to provide transition assistance to the Company during the severance period and thereafter, if necessary, on a limited consulting basis.
  • E&Y is officially on board
  • Volume14,016 Yesterday. Were cannonballing right along.
  • Osiris recruiting for a position in Human Resources
    One up numbering system suggests a new position. Notice that this position will be responsible for new employee orientation on on-boarding...sounds like the kind of position a growing firm might need.

    Human Resources Generalist Job ID 2017-1198

    Primary Purpose of Position: The Human Resources Generalist provides a wide variety of both complex and routine administrative services, including administering the Company’s employee benefit programs.
    The position reports to the Director, Human Resources.
    Principal Responsibilities:

    Responsibilities and duties include, but are not limited to, the following:
    Assist in development and implementation of personnel policies and procedures; prepare and maintain employee handbook and policies and procedures manual.
    Participate in developing department goals, objectives and systems.
    Assist in evaluation of reports, decisions, and results of department in relation to established goals. Recommend new approaches, policies, and procedures to continually improve efficiency of the department and services performed.
    Assume responsibility for employee orientation.
    Help coordinate and manage on-boarding of new employees.
    Enter new hires into payroll/HRIS system. Enter benefits and other information into ADP. Run reports as needed.
    Notify appropriate parties of hire and termination of employees.
    Maintain HRIS records and compile reports from the database.
    Perform benefits administration to include claims resolution, approving invoices for payment, enrolling employees in benefits, communicating benefit information to employees, assisting employees with benefits questions and changes.
    Resolve employee concerns related to health and welfare plans and function as liaison with various insurance carriers, broker and third party administrator.
    Maintain employee documentation as dictated by governing agencies.
    Help develop new benefits, wellness and employee initiatives.
    Maintain compliance with federal, state and local employment and benefits laws and regulations.
    Assist with third party audits, i.e. 401(k) SOX, audits of the personnel folders as needed and/or directed.
    Participate in administrative staff meetings.
    Project management.
    Maintain and process unemployment notices and potential charges in a timely, efficient manner. Attend hearings if necessary.
    Assist in administration of the performance appraisal program.
    Assist with recruitment tasks as needed (interviews).
    Report, maintain, and monitor all workers' compensation case files; follow-up on open cases.
    Perform other duties as assigned.

    https://jobs-osiris.icims.com/jobs/1198/human-resources-generalist/job

    Careers - Osiris Therapeutics, Inc.
    jobs-osiris.icims.com
  • Osiris is recruiting for a Regional Sales Specialist in Tampa, FL

    https://www.linkedin.com/jobs/view/308195895?trk=biz-overview-job-post

    Regional Sales Specialist - Tampa, FL
    Primary Purpose of Position:The Regional Sales Specialist is a field based position where the Specialist acts as an ambassador for Osiris Therapeutics Inc and its products. The Specialist will advise, demonstrate and guide clientele to products that
    www.linkedin.com
  • So, why we are above of "before delisting" pps? May be finance updates for 2015-16 are ready for publication? Or some Big Pharma suddenly realized that Prestige™ Lyotechnology have a huge value for multiple applications in medicine, biotechnology, etc? Definitely, somebody knows something and want to buy cheap shares. Question is who will sell them? During panic sell off May13-21 at around 15M shares of OSIR were sold at average $3 and after April 12 average daily volume become 50-80k. The buyers at $3 just don't want to realize 100% gain? Looks like that they wait for 200-300% gain after pps spike to $10-12 range... OSIR had such pps exactly 2 years ago before this problem with finance reports.
  • I went back and reread the NT10-Q filing from May 11, 2017. There is an interesting phrase that I dont previously recall, "so that the Company will be in a position to bring its filings with the Securities and Exchange Commission (“SEC”) up to date."

    The Company is working diligently to complete its previously announced restatement of prior period financial statements, transition to a new independent registered public accounting firm and complete its 2015 and 2016 financial statements as well as its first quarter 2017 (“Q1 2017) financial statements, so that the Company will be in a position to bring its filings with the Securities and Exchange Commission (“SEC”) up to date.

    http://investor.osiris.com/secfiling.cfm?filingID=1104659-17-31949&CIK=1360886

    Osiris Therapeutics - Notification of Late Filing
    investor.osiris.com
  • nothing....
  • Try buying some shares ... Got 225 at $6 and the ask jumped. Remember the "smoke and mirrors"? Well, someone collected about 100K shares under $6 while they went fishing last week.

    Pay no attention to the MDXG peanut gallery. There's room for more than one provider in the space ... stay tuned!
  • So how did 55K shares change hands without affecting the price?
  • Looking good!
  • NEV up on significant volume.
  • Osiris has developed a steady flow of placental tissue and are getting their tissue from four different tissue banks, located in California, New York, Maryland and Florida. Osiris Therapeutics, Inc. is registered with the FDA as a tissue establishment and accredited by the American Association of Tissue Banks (AATB).

    Having four different supply sources for raw materials implies that they are doing a big business and hopefully in a few more weeks (June/July) we'll get a glimpse of the dollars being generated.
  • Want to see how a real start-up bio-tech succeeds? Check out a company called MiMedx. Trades under the tickersymbol MDXG. They have no need for ignorant pumpers. They let revenues, products, senior management, and the pipeline do the talking. AMF suckers.
  • See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio. BioLargo recent 10Q states:
    • Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days
    • Woundcare market is over $6 Billion with high growth rate
    • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing
    • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost
    • Sales could commence late 2017
    • Sales and or licensing agreement/s could be very significant and fast
    • Company is now commercializing several other disruptive products in large markets

    http://www.clyramedical.com

    https://www.sec.gov/Archives/edgar/data/880242/000143774917009469/blgo20170331_10q.htm

    Clyra Medical | Make Life Better
    www.clyramedical.com